Higher risk for gestational diabetes and some poor newborn outcomes reported, but lower risk for some adverse pregnancy outcomes also found.
Programmed death-1 (PD-1) inhibition with pembrolizumab led to durable remission in 31.3% of patients with early acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) relapse after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results